| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1016: Elafibranor for previously treated primary biliary cholangitis |
|
Medicine details |
|
| Medicine name | elafibrinor |
| Formulation | oral |
| Reference number | 4543 |
| Indication | Treatment of primary biliary cholangitis in adults with inadequate response to ursodeoxycholic acid (UDCA) |
| Company | Genfit SA |
| BNF chapter | Gastro-intestinal system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 11/10/2024 |
| NICE guidance | TA1016: Elafibranor for previously treated primary biliary cholangitis |